We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.
The Southeast BIO (SEBIO) Investor & Partnering Forum expects more than 300 biotech and medtech investors, executives, university representatives and entrepreneurs at its 2017 event in Pinehurst November 14 to 16.
Celebrating its 19th year, the SEBIO Investor & Partnering Forum has built a loyal following, attracting thought leaders and investors from across the country. Registration is available at the door.
“They call us the food police.”
That’s how Greg Jaffe described his work as director of biotechnology for the Center for Science in the Public Interest (CSPI), speaking at the North Carolina Biotechnology Center’s seventh annual Biotech Roundtable.
Unlike most speakers at the event, Jaffe said the U.S. government’s decision not to regulate some products created by gene editing is questionable.
Clinical data company TARGET PharmaSolutions of Chapel Hill has entered into a new strategic partnership with a major pharmaceutical company and extended existing partnerships with two others to study a serious liver disease.
The Scullion Strategy Group, based in Greensboro, has inked an exclusive option agreement with Boston-based Brigham and Women’s Hospital (BWH) to license patent rights in semen analysis for veterinary use.
Morrisville-based TransEnterix has received clearance from the U.S. Food and Drug Administration to begin selling its Senhance surgical robotic system.
An appearance at a North Carolina Biotechnology Center event in 2016 convinced the CEO of a high-tech ag biotech startup to move his company from Massachusetts to the Research Triangle.
New genetic editing tools raise a host of ethical, legal, and regulatory questions in agricultural biotechnology innovation. That is the topic scientists, legal experts, and industry executives will tackle at an unusual event at the North Carolina Biotechnology Center Oct. 24.
The Medical Innovators Collaborative (MEDIC) has launched its first fundraising campaign to support its work as a medical device hub in the Research Triangle Park.
PlantResponse, a plant biotechnology company based in Madrid, has established its North American headquarters in North Carolina’s Research Triangle Park and is looking for permanent facilities in the area.
Pelican Therapeutics, a subsidiary of Durham-based Heat Biologics Inc., has entered a service agreement with Geneva-based Selexis SA to advance development of Pelican’s cancer-fighting therapy candidates.
Fennec Pharmaceuticals, a specialty pharmaceutical company with executive headquarters in the Research Triangle Park, is making a difference for children with hearing loss.
Greensboro-based Piedmont Animal Health, a developer of health products for companion animals, has gained a strategic equity investment from the life science division of Sumitomo Corp., a Fortune 500 company based in Tokyo.
Humacyte, a Morrisville-based regenerative medicine company bootstrapped with early funding from the North Carolina Biotechnology Center, has received more than $18 million from three sources to help test and commercialize its bioengineered blood vessel, Humacyl.
